Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cerebral palsy therapeutics - Kidswell Bio/Nagoya University Hospital/Tokyo Metropolitan Institute of Medical Science/Tokyo Medical and Dental University

X
Drug Profile

Cerebral palsy therapeutics - Kidswell Bio/Nagoya University Hospital/Tokyo Metropolitan Institute of Medical Science/Tokyo Medical and Dental University

Latest Information Update: 05 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kidswell Bio; Nagoya University Hospital; Tokyo Medical and Dental University; Tokyo Metropolitan Institute of Medical Science
  • Developer Kidswell Bio; Nagoya University Hospital
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Cerebral palsy

Most Recent Events

  • 31 Oct 2023 Clinical trials in Cerebral palsy in Japan (Parenteral)
  • 01 Jul 2021 Gene Techno Science is now called Kidswell Bio
  • 22 Jan 2020 Kidswell Bio (formerly Gene Techno Science) executes a joint research agreement with Tokyo Metropolitan Institute of Medical Science, Nagoya University Hospital, and Tokyo Medical and Dental University for research and development of new therapeutic treatments for Cerebral palsy
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top